Downloads
Abstract
Objective: The study aims to determine the relationship between the characteristics of Tacrolimus trough concentration (C0 TAC) from month 2 to month 12 after kidney transplantation with some clinical outcomes, thereby initially determining the optimal C0 TAC target for patients after kidney transplantation.
Methods: A longitudinal retrospective observational study on 257 living - donor kidney transplant patients. Regression analysis was used to evaluate the relationship between mean and coefficient of variation of C0 TAC during the period from 2 months to 12 months after transplantation with clinical outcomes at 12 months post-transplantation, including eGFR, proteinuria, biopsy-proven acute rejection, acute kidney injury, CMV and PCP infection, hospitalization for non - CMV and PCP infections.
Results: Patients with mean C0 TAC < 7 ng/ml had the highest risk of eGFR decline and this risk decreased in patients with higher mean C0 TAC, especially in the C0 TAC ≥ 9 ng/ml group (OR = 0.206; p = 0.001; CI 95%: 0.079 - 0.536). Patients with mean C0 TAC 7 - 7.9 ng/ml had a lower risk of acute kidney injury in the first 12 months after transplantation than the group with C0 TAC < 7 ng/ml (OR = 0.234; p = 0.044). The risk of acute rejection in the first 12 months after transplantation tended to decrease in patients with C0 TAC 7 - 7.9 and 8 - 8.9 ng/ml (ORs are respectively 0.612 and 0.25), the difference is not statistically significant. Patients with mean C0 TAC ≥ 9 ng/ml had a higher risk of CMV infection than patients with C0 TAC < 7 ng/ml (OR = 3.737; p = 0.012). The events of acute kidney injury, acute rejection, and hospitalization for non - CMV and PCP infections were more likely to occur in patients with a higher TAC coefficient of variation (ORs are respectively 1.045, 1.049, 1.044 with p = 0.01; 0.049 and 0.001).
Conclusion: The optimal treatment target of TAC trough level needs to be considered based on different clinical outcomes. A treatment target of 7 - 8.9 ng/ml may be considered for transplant patients during the period from month 2 to month 12 after kidney transplantation.
References
Sellarés J, De Freitas D, Mengel M, Reeve J, Einecke G, Sis B, et al., Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. American Journal of Transplantation, 2012;12(2):388-399.
Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et al., Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clinical infectious diseases, 2008;46(6):840-846.
Yoon S-H, Cho J-H, Jung H-Y, Choi J-Y, Park S-H, Kim Y-L, et al. Clinical impact of BK virus surveillance on outcomes in kidney transplant recipients. in Transplantation Proceedings. 2015. Elsevier.
Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw L, Angelis M, et al., Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept trial. American Journal of Transplantation, 2009;9(7):1607-1619.
Ekberg H, Tedesco-Silva H, Demirbas A, Vítko Š, Nashan B, Gürkan A, et al., Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine, 2007;357(25):2562-2575.
Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Roth D, Goldstein MJ, et al., Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transplant International, 2016;29(2):216-226.
Israni AK, Riad SM, Leduc R, Oetting WS, Guan W, Schladt D, et al., Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. Transplant International, 2013;26(10):982-989.
Staatz C, Taylor P, Tett S, Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrology Dialysis Transplantation, 2001;16(9):1905-1909.
Van Gelder T, Within - patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney international, 2014;85(6):1267-1268.
Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, et al., Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metabolism and Disposition, 1995;23(12):1315-1324.
Park Y, Lee H, Eum SH, Kim HD, Ko EJ, Yang CW, et al., Intrapatient variability in tacrolimus trough levels over 2 Years affects long-term allograft outcomes of kidney transplantation. Frontiers in immunology, 2021;12:746013.
Rodrigo E, San Segundo D, Fernández-Fresnedo G, López-Hoyos M, Benito A, Ruiz JC, et al., Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. Transplantation, 2016;100(11):2479-2485.
Eckardt K-U, Kasiske BL, Zeier MG, KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation, 2009;9:S1-S155.
Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al., Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Therapeutic drug monitoring, 2009;31(2):139-152.
Brunet M, Van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, et al., Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Therapeutic drug monitoring, 2019;41(3):261-307.
Nguyen TVA, Nguyen HD, Nguyen TLH, Le VT, Nguyen XK, Tran VT, et al., Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation. BMC nephrology, 2023;24(1):131.
Richards KR, Hager D, Muth B, Astor BC, Kaufman D, Djamali A, Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. Transplantation, 2014;97(10):986-991.
Rojas AM, Hesselink DA, van Besouw NM, Dieterich M, de Kuiper R, Baan CC, et al., High tacrolimus intrapatient variability and subtherapeutic immunosuppression are associated with adverse kidney transplant outcomes. Therapeutic Drug Monitoring, 2022;44(3):369.
Park Y, Lee H, Eum SH, Ko EJ, Min JW, Yoon S-H, et al., Combined impact of the inter and intra-patient variability of tacrolimus blood level on allograft outcomes in kidney transplantation. Frontiers in immunology, 2022;13:1037566.
| Published | 10-12-2023 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 93 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.93.7 | |
| Keywords | Ghép thận, kết cục lâm sàng, tacrolimus, nồng độ đáy, hệ số biến thiên Kidney transplantation, clinical outcomes, tacrolimus, trough level, inpatient variability |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital